Search Results

You searched for all publications:

with publication states 'Published (Approved)'

Search Again...

These results only include publications that have been reviewed and processed by Diamond Light Source. To also view papers that have not yet been processed click here.

You can use the folder icon under Actions to collate papers as required. You can then click on View Folder in the left-hand navigation to review and/or download your folder.

Exact matches
Related results

5 items found (0 items not approved), displaying all items.1

Instruments / Technical Area	Publication Details	Published
I04-Macromolecular Crystallography	Structure-based design of potent and orally active isoindolinone inhibitors of MDM2-p53 protein–protein interaction Gianni Chessari , Ian R. Hardcastle , Jong Sook Ahn , Burcu Anil , Elizabeth Anscombe , Ruth H. Bawn , Luke D. Bevan , Timothy J. Blackburn , Ildiko Buck , Celine Cano , Benoit Carbain , Juan Castro , Ben Cons , Sarah J. Cully , Jane A. Endicott , Lynsey Fazal , Bernard T. Golding , Roger J. Griffin , Karen Haggerty , Suzannah J. Harnor , Keisha Hearn , Stephen Hobson , Rhian S. Holvey , Steven Howard , Claire E. Jennings , Christopher N. Johnson , John Lunec , Duncan C. Miller , David R. Newell , Martin E. M. Noble , Judith Reeks , Charlotte H. Revill , Christiane Riedinger , Jeffrey D. St. Denis , Emiliano Tamanini , Huw Thomas , Neil T. Thompson , Mladen Vinković , Stephen R. Wedge , Pamela A. Williams , Nicola E. Wilsher , Bian Zhang , Yan Zhao Journal Of Medicinal Chemistry DOI: 10.1021/acs.jmedchem.0c02188 Show Abstract ▼ Abstract: Inhibition of murine double minute 2 (MDM2)-p53 protein–protein interaction with small molecules has been shown to reactivate p53 and inhibit tumor growth. Here, we describe rational, structure-guided, design of novel isoindolinone-based MDM2 inhibitors. MDM2 X-ray crystallography, quantum mechanics ligand-based design, and metabolite identification all contributed toward the discovery of potent in vitro and in vivo inhibitors of the MDM2-p53 interaction with representative compounds inducing cytostasis in an SJSA-1 osteosarcoma xenograft model following once-daily oral administration.	Mar 2021
B21-High Throughput SAXS I04-1-Macromolecular Crystallography (fixed wavelength)	Discriminative SKP2 interactions with CDK-cyclin complexes support a cyclin a-specific role in p27KIP1 degradation Marco Salamina , Bailey C. Montefiore , Mengxi Liu , Daniel J. Wood , Richard Heath , James R. Ault , Lan-Zhen Wang , Svitlana Korolchuk , Arnaud Basle , Martyna Pastok , Judith Reeks , Natalie J. Tatum , Frank Sobott , Stefan T. Arold , Michele Pagano , Martin E. M. Noble , Jane A. Endicott Journal Of Molecular Biology 433 DOI: 10.1016/j.jmb.2020.166795 Diamond Proposal Number(s): [13587, 16970] Open Access Show Abstract ▼ Abstract: The SCFSKP2 ubiquitin ligase relieves G1 checkpoint control of CDK-cyclin complexes by promoting p27KIP1 degradation. We describe reconstitution of stable complexes containing SKP1-SKP2 and CDK1-cyclin B or CDK2-cyclin A/E, mediated by the CDK regulatory subunit CKS1. We further show that a direct interaction between a SKP2 N-terminal motif and cyclin A can stabilize SKP1-SKP2-CDK2-cyclin A complexes in the absence of CKS1. We identify the SKP2 binding site on cyclin A and demonstrate the site is not present in cyclin B or cyclin E. This site is distinct from but overlapping with features that mediate binding of p27KIP1 and other G1 cyclin regulators to cyclin A. We propose that the capacity of SKP2 to engage with CDK2-cyclin A by more than one structural mechanism provides a way to fine tune the degradation of p27KIP1 and distinguishes cyclin A from other G1 cyclins to ensure orderly cell cycle progression.	Mar 2021
I03-Macromolecular Crystallography I04-1-Macromolecular Crystallography (fixed wavelength) I04-Macromolecular Crystallography I24-Microfocus Macromolecular Crystallography	FragLites - minimal, halogenated fragments displaying pharmacophore doublets. An efficient approach to druggability assessment and hit generation Daniel J. Wood , José Daniel Lopez-fernandez , Leanne E. Knight , Islam Al-khawaldeh , Conghao Gai , Shengyin Lin , Mathew P. Martin , Duncan C. Miller , Celine Cano , Jane A. Endicott , Ian R. Hardcastle , Martin E. M. Noble , Michael J. Waring Journal Of Medicinal Chemistry DOI: 10.1021/acs.jmedchem.9b00304 Show Abstract ▼ Abstract: Identifying ligand binding sites on proteins is a critical step in target-based drug discovery. Current approaches to this require resource intensive screening of large libraries of lead-like or fragment molecules. Here we describe an efficient and effective experimental approach to mapping interaction sites using a set of halogenated compounds expressing paired hydrogen-bonding motifs, termed FragLites. The FragLites identify productive drug-like interactions, which are identified sensitively and unambiguously by X-ray crystallography, exploiting the anomalous scattering of the halogen substituent. This mapping of protein interaction surfaces provides an assessment of druggability and can identify efficient start points for the de novo design of hit molecules incorporating the interacting motifs. The approach is illustrated by mapping cyclin-dependent kinase 2, which successfully identifies orthosteric and allosteric sites. The hits were rapidly elaborated to develop efficient lead-like molecules. Hence, the approach provides a new method of identifying ligand sites, assessing tractability and discovering new leads.	Mar 2019
	Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach Duncan C. Miller , Mathew P. Martin , Santosh Adhikari , Alfie Brennan , Jane A. Endicott , Bernard T. Golding , Ian R. Hardcastle , Amy Heptinstall , Stephen Hobson , Claire Jennings , Lauren Molyneux , Yvonne Ng , Stephen R. Wedge , Martin Noble , Celine Cano Organic & Biomolecular Chemistry 21 DOI: 10.1039/C8OB00099A Show Abstract ▼ Abstract: ATAD2 is an ATPase that is overexpressed in a variety of cancers and associated with a poor patient prognosis. This protein has been suggested to function as a cofactor for a range of transcription factors, including the proto-oncogene MYC and the androgen receptor. ATAD2 comprises an ATPase domain, implicated in chromatin remodelling, and a bromodomain which allows it to interact with acetylated histone tails. Dissection of the functional roles of these two domains would benefit from the availability of selective, cell-permeable pharmacological probes. An in silico evaluation of the 3D structures of various bromodomains suggested that developing small molecule ligands for the bromodomain of ATAD2 is likely to be challenging, although recent reports have shown that ATAD2 bromodomain ligands can be identified. We report a structure-guided fragment-based approach to identify lead compounds for ATAD2 bromodomain inhibitor development. Our findings indicate that the ATAD2 bromodomain can accommodate fragment hits (Mr < 200) that yield productive structure–activity relationships, and structure-guided design enabled the introduction of selectivity over BRD4.	Feb 2018
I04-1-Macromolecular Crystallography (fixed wavelength)	Cyclin-Dependent Kinase (CDK) Inhibitors; Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines Christopher R Coxon , Elizabeth Anscombe , Suzannah Jane Harnor , Mathew P. Martin , Benoit Jean-pierre Carbain , Bernard Thomas Golding , Ian Robert Hardcastle , Lisa K Harlow , Svitlana Korolchuk , Christopher J. Matheson , David R. Newell , Martin E. M. Noble , Mangaleswaran Sivaprakasam , Susan J. Tudhope , David M. Turner , Lan-zhen Wang , Stephen R Wedge , Christopher Wong , Roger John Griffin , Jane A. Endicott , Celine Cano Journal Of Medicinal Chemistry DOI: 10.1021/acs.jmedchem.6b01254 Diamond Proposal Number(s): [13587] Show Abstract ▼ Abstract: Purines and related heterocycles substituted at C-2 with 4’-sulfamoylanilino and at C-6 with a variety of groups have been synthesized with the aim of achieving selectivity of binding to CDK2 over CDK1. 6-Substituents that favour competitive inhibition at the ATP binding site of CDK2 were identified and typically exhibited 10-80-fold greater inhibition of CDK2 compared to CDK1. Most impressive was 4-((6-([1,1'-biphenyl]-3-yl)-9H-purin-2-yl)amino) benzenesulfonamide (73) that exhibited high potency towards CDK2 (IC50 0.044 μM), but was ~ 2000-fold less active towards CDK1 (IC50 86 μM). This compound is therefore a useful tool for studies of cell cycle regulation. Crystal structures of inhibitor-kinase complexes showed that the inhibitor stabilizes a glycine-rich loop conformation that shapes the ATP ribose binding pocket, and that is preferred in CDK2, but has not been observed in CDK1. This aspect of the active site may be exploited for the design of inhibitors that distinguish between CDK1 and CDK2.	Dec 2016

Publications Database

Search Results

You searched for all publications:

Search Again...

Subject Areas (check all that apply) select all

Instruments used to collect data (check all that apply) select all

Collaborations involved (check all that apply) select all

Diamond Offline Facilities used

Relevant Technical Areas (check all that apply) select all

Menu for Anonymous User